Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of INS062 and PK/PD of HR20014 in Healthy Subjects
NCT05719961Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jan 2023
- Primary completion
- Jul 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of INS062 and HR20014 in diabetes mellitus (DM) (4 arms), sponsored by Hengrui. Primary endpoints: Area under the concentration-time curve, Maximum concentration and 4 more. Status: unknown.
02
Drugs
INS062HR20014
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05719961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719961.